Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion - Scorecard - MDSpire
Clinical Scorecard: Correction: Case Report on Complete Response and Extended Survival with Alectinib in a NSCLC Patient Exhibiting a Rare WDR43::ALK Structural Deletion
At a Glance
Category
Detail
Condition
Non-Small Cell Lung Cancer (NSCLC)
Key Mechanisms
Alectinib targeting ALK mutations
Target Population
Patients with NSCLC harboring WDR43::ALK structural deletion
Care Setting
Oncology
Key Highlights
Correction of errors in published figures
Complete response to alectinib observed
Prolonged survival noted in case report
Rare WDR43::ALK structural deletion identified
Updated figures provided for accuracy
Guideline-Based Recommendations
Diagnosis
Management
Consider alectinib for patients with ALK-positive NSCLC
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with metastatic NSCLC and specific ALK alterations
Alectinib shows efficacy in rare ALK structural deletions
Clinical Best Practices
Verify genetic alterations in NSCLC patients
Ensure accurate representation of clinical data in publications
